Diagnostics firm Hologic Inc. saw its revenues increase 2 percent to $625 million in its second fiscal quarter, powered largely by its 3-D mammography technology. Breast health revenues grew 8.5 percent to $238.7 million, while skeletal health revenues rose 4.7 percent to $23.5 million. The company attributed the increases to growing sales of bone densitometry and 3-D mammography systems. Partially offsetting these increases was an expected overall sales decline of 2-D systems. Meanwhile, diagnostics revenues fell 1.9 percent to $290.8 million and gynecological surgical revenues dropped 2.2 percent to $72.0 million. The company attributed the decline to loss of revenue from subsidiary Lifecodes, which it sold a year ago for $10.6 million, and decreases in pap test sales in the US. Partially offsetting these declines were increased sales of the Aptima product line and blood screening revenues. “To be clear, we still have plenty of work to do in order to consistently improve our operating results, achieve long-term growth and maximize value creation,” said President and CEO Stephen MacMillan. The company closed its second quarter March 29; it expects third-quarter revenues of $615 million to $625 million. Eric Compton was recently appointed chief operating officer, and Claus Egstrand was recently named senior vice president and international general manager.